1.375
전일 마감가:
$1.45
열려 있는:
$1.46
하루 거래량:
325.14K
Relative Volume:
0.51
시가총액:
$20.85M
수익:
$486.00K
순이익/손실:
$-28.43M
주가수익비율:
-0.4878
EPS:
-2.8189
순현금흐름:
$-26.75M
1주 성능:
+14.58%
1개월 성능:
+29.72%
6개월 성능:
-50.18%
1년 성능:
-31.25%
Vyne Therapeutics Inc Stock (VYNE) Company Profile
명칭
Vyne Therapeutics Inc
전화
800-775-7936
주소
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
VYNE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VYNE
Vyne Therapeutics Inc
|
1.3708 | 18.66M | 486.00K | -28.43M | -26.75M | -2.8189 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
473.97 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
570.72 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
330.56 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
590.65 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.24 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-11-18 | 개시 | BTIG Research | Buy |
2021-12-06 | 재개 | H.C. Wainwright | Buy |
Vyne Therapeutics Inc 주식(VYNE)의 최신 뉴스
What drives VYNE Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - Autocar Professional
VYNE Therapeutics Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional
Is VYNE Therapeutics Inc. a good long term investmentMassive profits - Autocar Professional
What analysts say about VYNE Therapeutics Inc. stockSuperior portfolio returns - Autocar Professional
Does VYNE Therapeutics Inc. stock pay reliable dividendsFree Capital Allocation Plans - Newser
How VYNE Therapeutics Inc. stock performs during market volatilityShort Term High Return Strategy - Newser
Why VYNE Therapeutics Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser
What makes VYNE Therapeutics Inc. stock price move sharplyIntraday Trade Ideas - Newser
VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress - MSN
VYNE Therapeutics: A High-Stakes Gamble on Vitiligo and Psoriasis - AInvest
Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study - TipRanks
VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 9.5% – Should You Sell? - Defense World
VYNE Unblinds Early VYN202 Data After Safety Pause - Dermatology Times
BTIG reiterates Buy rating on VYNE Therapeutics stock ahead of vitiligo trial data - Investing.com Canada
H.C. Wainwright reiterates Buy rating on VYNE Therapeutics stock amid clinical hold update - Investing.com Canada
NOVT secures new $1B credit facility, extends maturity to 2030 | VYNE SEC FilingForm 4 - Stock Titan
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - The Manila Times
FDA partially lifts clinical hold on VYNE’s VYN202 psoriasis trial By Investing.com - Investing.com UK
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 | VYNE Stock News - GuruFocus
VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14% - Nasdaq
Celebrating World Vitiligo Day 2025 with Dermatology Times - Dermatology Times
Vitiligo Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - The Globe and Mail
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 46.8% - Defense World
Jane Street Group LLC Invests $68,000 in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
Northern Trust Corp Has $80,000 Stock Holdings in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges By Investing.com - Investing.com South Africa
VYNE Therapeutics (NASDAQ:VYNE) Upgraded at Wall Street Zen - Defense World
VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges - Investing.com India
VYNE Therapeutics (NASDAQ:VYNE) Cut to Sell at Wall Street Zen - Defense World
VYNE Stock Touches 52-Week Low at $1.17 Amid Market Challenges - Investing.com
VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail
VYNE Therapeutics Reports Q1 2025 Financial Results - TipRanks
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating - TipRanks
Vyne Therapeutics Inc (VYNE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):